Bionomics Limited (BNOX)
Company Description
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States.
The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder.
It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Bionomics Limited has a licensing agreement with Merck & Co., Inc.
The company was incorporated in 1996 and is based in Eastwood, Australia.

Country | AU |
IPO Date | Dec 16, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Dr. Spyridon Papapetropoulos M.D., Ph.D. |
Contact Details
Address: 200 Greenhill Road Eastwood, SA AU | |
Website | https://www.bionomics.com.au |
Stock Details
Ticker Symbol | BNOX |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001191070 |
CUSIP Number | 09063M205 |
ISIN Number | US09063M2052 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Executive Officer, President & Director |
Timothy M. Cunningham CPA, M.B.A. | Chief Financial Officer |
Adrian Hinton BEC, F.C.A. | Financial Controller |
Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations |
Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
Elizabeth Doolin | Senior Vice President of Clinical Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 23, 2024 | 8-K | Current Report |
Dec 23, 2024 | POS AM | Filing |
Dec 23, 2024 | POS AM | Filing |
Dec 23, 2024 | 15-12G | Filing |
Dec 16, 2024 | 8-K | Current Report |
Dec 12, 2024 | 8-K | Current Report |
Nov 25, 2024 | S-3/A | [Amend] Filing |
Nov 21, 2024 | 8-K | Current Report |
Nov 18, 2024 | S-3 | Filing |
Nov 14, 2024 | 10-Q | Quarterly Report |